Pancreatic Cancer Research

ResearcherUniversity of PisaNo recent work listed

Lorenzo Fornaro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0187-5904; OpenAlex author ID A5036615333. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 4, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2016: 3 papers · 2017: 1 paper, 1 trial · 2018: none · 2019: 5 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 2 papers

Papers 15

  1. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  2. Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. Co-author DOI 10.3390/cancers15030900↗
  3. Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. Co-author DOI 10.1007/s13304-020-00883-7↗
  4. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-p… Co-author DOI 10.1038/s41397-020-00203-7↗
  5. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Co-author DOI 10.3390/cancers13153738↗
  6. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Last author DOI 10.1016/j.ejca.2020.06.031↗
  7. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
  8. FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer. Reply. First author DOI 10.1056/nejmc1900712↗
  9. Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of … First author DOI 10.1200/jco.19.00127↗
  10. The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. Co-author DOI 10.2217/pgs-2018-0149↗
  11. Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Coh… First author DOI 10.3390/cancers11070939↗
  12. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41598-017-08297-z↗
  13. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. Co-author DOI 10.1002/ijc.30125↗
  14. Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'. First author DOI 10.1038/bjc.2016.69↗
  15. Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. Co-author DOI 10.2217/fon.16.16↗

Trials 1

  1. Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX Principal investigator NCT03590275↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Caterina Vivaldi · 14 shared papers, 2016–2023 · strength 1.35
  2. Enrico Vasile · 14 shared papers, 2016–2023 · strength 1.35
  3. Silvia Catanese · 7 shared papers, 2016–2021 · strength 0.62
  4. Irene Pecora · 4 shared papers, 2019–2021 · strength 0.39
  5. Eleonora Rofi · 4 shared papers, 2017–2021 · strength 0.38
  6. Marzia Del Re · 4 shared papers, 2017–2021 · strength 0.38
  7. Romano Danesi · 4 shared papers, 2017–2021 · strength 0.38
  8. Chiara Caparello · 4 shared papers, 2016–2017 · strength 0.26
  9. Francesco Leone · 2 shared papers, 2019–2023 · strength 0.22
  10. Francesco Montagnani · 2 shared papers, 2019–2023 · strength 0.22
  11. Daniela Campani · 2 shared papers, 2019–2021 · strength 0.19
  12. Emanuele F. Kauffmann · 2 shared papers, 2019–2021 · strength 0.19
  13. Andrea Cacciato Insilla · 2 shared papers, 2019–2021 · strength 0.19
  14. Niccolò Napoli · 2 shared papers, 2019–2021 · strength 0.19
  15. Ugo Boggi · 2 shared papers, 2019–2021 · strength 0.19
  16. Mario Scartozzi · 1 shared paper, 2023 · strength 0.15
  17. Valentina Fanotto · 1 shared paper, 2023 · strength 0.15
  18. Debora Basile · 1 shared paper, 2023 · strength 0.15
  19. Giuseppe Aprile · 1 shared paper, 2023 · strength 0.15
  20. Kalliopi Andrikou · 1 shared paper, 2020 · strength 0.09
  21. Giulia Rovesti · 1 shared paper, 2020 · strength 0.09
  22. Vincenzo Formica · 1 shared paper, 2020 · strength 0.09
  23. Niccola Funel · 1 shared paper, 2019 · strength 0.09
  24. Pasquale Lombardi · 1 shared paper, 2019 · strength 0.07
  25. Déwi Vernerey · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.